Literature DB >> 6109737

Clearance of immunoreactive somatostatin by perfused rat liver.

H Sacks, L C Terry.   

Abstract

Other investigators have demonstrated that concentrations of immunoreactive somatostatin (IRS) are higher in blood from the hepatic portal vein or its tributaries than in blood from the hepatic or peripheral systemic veins of man and animals. This suggests that there is hepatic extraction of IRS from the portal system in vivo. In the rat, portal vein plasma IRS is reported to be heterogeneous and to contain, in part, a 1,600 mol wt form of IRS which is immunochemically similar to synthetic somatostatin and not significantly bound to high molecular weight plasma protein. Our study was undertaken to determine directly whether unbound synthetic cyclic somatostatin was cleared by the rat liver perfused through the hepatic portal vein in vitro with a recirculating, plasma-free, erythrocyte-containing perfusate. At 37 degrees C and pH 7.40, perfusate IRS, at initial concentrations (1,728 pg/ml) within the range previously reported in rat portal venous blood, was removed by the liver at a rate commensurate with first-order kinetics. Hepatic clearance was 0.84+/-0.04 ml/min per g postperfusion wet weight (SE). Hepatic extraction was 36+/-2%, and t((1/2)) was 20.0+/-1.3 min. Recovery of IRS from the perfusate without the liver was >85%, excluding significant degradation by the medium. Clearance, extraction, and t((1/2)) of IRS were not changed by an unphysiologic IRS concentration (621,500 pg/ml), or by pharmacologic concentrations of insulin (8.2 muM) or glucagon (2.9 muM). The t((1/2)) was prolonged significantly to 28.2+/-1.9 and 45.6+/-4.7 min during perfusions at liver temperatures of 25 degrees and 16 degrees C, respectively. At 37 degrees C, the t((1/2)) was also significantly increased to 28.7+/-3.2 and 24.2+/-1.1 min at perfusate pH 7.06 and 6.78, respectively. These studies indicate that the rat liver clears unbound IRS from the perfusate by a first-order kinetic process that is (a) unsaturable at pharmacologic concentrations, (b) temperature-sensitive and, to a lesser extent, influenced by lowered pH, and (c) not affected by insulin and glucagon. The liver would appear to play an important role in the metabolism of the 1,600 mol wt form of somatostatin. Clearance of endogenous IRS by the liver should be considered in the interpretation of IRS concentrations in the peripheral systemic veins.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6109737      PMCID: PMC370583          DOI: 10.1172/JCI110050

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Studies on the inhibition of insulin release, glycogenolysis and gluconeogenesis by somatostatin in the rat islets of langerhans and isolated hepatocytes.

Authors:  J R Oliver; S R Wagle
Journal:  Biochem Biophys Res Commun       Date:  1975-02-03       Impact factor: 3.575

2.  Inactivation of somatostatin (GH-RIH) and its an analogs by crude and partially purified rat brain extracts.

Authors:  N Marks; F Stern
Journal:  FEBS Lett       Date:  1975-07-15       Impact factor: 4.124

3.  Intracellular acidbase relations and intracellular buffers.

Authors:  E D ROBIN; R J WILSON; P A BROMBERG
Journal:  Ann N Y Acad Sci       Date:  1961-06-17       Impact factor: 5.691

4.  Glucagon antibodies and an immunoassay for glucagon.

Authors:  R H UNGER; A M EISENTRAUT; M S McCALL; L L MADISON
Journal:  J Clin Invest       Date:  1961-07       Impact factor: 14.808

5.  Binding and degradation of 125I-insulin by rat hepatocytes.

Authors:  S Terris; D F Steiner
Journal:  J Biol Chem       Date:  1975-11-10       Impact factor: 5.157

6.  Properties of soluble somatostatin-binding protein.

Authors:  N Ogawa; T Thompson; H G Friesen; J B Martin; P Brazeau
Journal:  Biochem J       Date:  1977-08-01       Impact factor: 3.857

7.  Effects of somatostatin on the hepatic adenylate cyclase system in the rat.

Authors:  F Vinicor; G Higdon; C M Clark
Journal:  Endocrinology       Date:  1977-10       Impact factor: 4.736

8.  The effect of hypophysectomy on somatostatin-like immunoreactivity in discrete hypothalamic and extrahypothalamic nuclei.

Authors:  L C Terry; W R Crowley
Journal:  Endocrinology       Date:  1980-12       Impact factor: 4.736

9.  Measurement, characterization, and source of somatostatin-like immunoreactivity in human amniotic fluid.

Authors:  D Fitz-Patrick; Y C Patel
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

10.  Gluconeogenesis in the perfused rat liver.

Authors:  R Hems; B D Ross; M N Berry; H A Krebs
Journal:  Biochem J       Date:  1966-11       Impact factor: 3.857

View more
  5 in total

1.  Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog.

Authors:  K S Polonsky; J B Jaspan; M Berelowitz; D S Emmanouel; J Dhorajiwala
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 2.  Endogenous somatostatin and the gut.

Authors:  M R Lucey
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

Review 3.  Biochemistry and physiology of gastrointestinal somatostatin.

Authors:  M R Lucey; T Yamada
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

4.  Contribution of the pancreas to circulating somatostatin-like immunoreactivity in the normal dog.

Authors:  G J Taborsky; J W Ensinck
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

5.  Somatostatin reduces gastric mucosal blood flow in normal subjects but not in patients with cirrhosis of the liver.

Authors:  A Sonnenberg; C West
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.